Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Rate of measured residual disease (MRD) negative complete remission (CR)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and
 venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in
 treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine
 is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes,
 which are genes that help control cell growth. Venetoclax is in a class of medications called
 B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking
 Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications
 called kinase inhibitors. It works by blocking the action of a certain naturally occurring
 substance that may be needed to help cancer cells multiply. This study may help doctors find
 out if these different approaches are better than the usual approaches. To decide if they are
 better, the study doctors are looking to see if the study drugs lead to a higher percentage
 of patients achieving a deeper remission compared to the usual approach.